Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-778-1 | CAS number: 7726-95-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Original reference in a foreign language
Data source
Reference
- Reference Type:
- publication
- Title:
- [Experimental data for hygienic standardization of bromine and hydrogen bromide content in the air of working areas]
- Author:
- Ivanov NG, AM Klyachkina, AL Germanova
- Year:
- 1 976
- Bibliographic source:
- Gig. Tr. Prof. Zabol. 20:36-39.
Materials and methods
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Bromine
- EC Number:
- 231-778-1
- EC Name:
- Bromine
- Cas Number:
- 7726-95-6
- Molecular formula:
- Br2
- IUPAC Name:
- dibromine
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other:
- Sex:
- male/female
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure:
- not specified
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 4 month exposure, with 1 month recovery group
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
12.4 mg/m3
Basis:
other: ± 1.4 mg/m3
- Remarks:
- Doses / Concentrations:
1.4 mg/m3
Basis:
other: ± 0.1 mg/m3
- Remarks:
- Doses / Concentrations:
0.16 mg/m3
Basis:
other: ± 0.632 mg/m3
- No. of animals per sex per dose:
- 8 rats or 6 rabbits were the minimum statistical groups
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: The LIMir from the acute study, 9 times lower than the LIMir and 80 times lower than LIMir
The LIMir was the air concentration seen as the limiting dose for irritation, approximately 10 mg/m^3 for a 4 hour exposure. In the chronic exposure experiment, actual concentrations were 12.4 +/- 1.4 mg/m^3, 1.4 +/-0.1 mg/m^3, and 0.16 +/- 0.632 mg/m^3.
- Post-exposure recovery period in satellite groups: 1 month
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Primarily respiratory tract irritation
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Primarily respiratory tract irritation
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Decreased body weights
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- thyroid and adrenal gland
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Respiratory system
- Details on results:
- Exposure to 12.4 +/- 1.4 mg/m^3 (1.9 ppm) for 4 months caused effects on the respiratory, olfactory, and endocrine systems. Less pronounced effects were seen with exposure to 1.4 +/- 0.1 mg/m^3 (0.2 ppm) for four months, which were seen to be reversible in a 1 month recovery group. No effects were seen as a result of exposure to 0.16 mg/m^3 (0.02 ppm) for 4 months. See table in Other information on results
The high exposure concentration caused pronounced toxic effects. Rats showed decreased body weights, and effects on the functions of the nervous, endocrine and cardiovascular systems. Disruption of the respiratory system was seen at all periods of observation throughout the exposure. Respiratory rates in the rats exposed to the high concentration were reduced compared to control, and also at 2 months of exposure. Hitopathology in the high dose exposed animals was primarily respiratory lesions, with signs of moderate protein dystrophy were seen in kidney and liver. In a parallel experiment using rabbits, respiratory rate effects were also seen at 2 and 3 months after start of exposure, and the olfactory thresholds to exposure to aromatic substances were increased in rabbits. At 1 month after start of exposures in rabbits, the olfactory threshold to tar increased four fold, and after 4 months, increased 10 fold. These changes in rabbits persisted even in the 1 month recovery period. Histopathology of rabbits showed that the respiratory system was the main lesion, with moderate protein dystrophy in the liver and kidneys also.
With exposure to the middle concentration (1.4 mg/m^3 +/- 0.1), decreased excitability of the nervous system was measured at 3 months. Changes in the endocrine system were somewhat biphasic. At 2 months of exposure, thyroid uptake of 131Iodine was increased in the treated animals compared to controls, and weight coefficients of the thyroid glands were increased. At 4 months, the thyroid functions appeared decreased as indicated by decreased lablled iodine uptake. Adrenal weights were increased at 3 months of exposure. The respiratory effects in the mid-concentration group were more constant - respiratory rates were decreased in the rats at 2 months. Rats showed progressive decrease in olfactory acuity during the exposure period. Decrease in olfactory acuity was closely associated with the changes in the mucous membranes of the upper respiratory tract. The histopathology seen in the respiratory system of the high and mid concentration exposure groups included thickening of the mucous membrane and submucosal layers, edema, increased number of goblet cells in the epithelium, desquamation of epithelial cells, and discharge of mucus into the clear spaces of the upper respiratory tracts. Effects were more pronouced in animals exposed to the concentration representing LIMir (the highest concentration). Effects were less in the mid-dose concentration, and all the tested characteristics in this dose group normalized in the 1 month recovery period. this suggested that the middle concentration was close to the LIMch (limit for chronic effects). The lowest concentration (0.16 mg/m^3) was seen to cause no adverse effects in the selected endpoints.
Effect levels
open allclose all
- Dose descriptor:
- NOAEC
- Effect level:
- 0.16 mg/m³ air
- Basis for effect level:
- other: overall effects: no effects seen. This concentration was considered 80 times lower than the limit of irritation (LIM ir).
- Dose descriptor:
- LOAEC
- Effect level:
- 1.4 mg/m³ air
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
4 month repeated dose study in rats
Effect Observed |
Control Group |
Concentration Group |
Significance Level or Comment |
Respiratory rate (per minute) Month 1 Month 2 |
Control 163 +/- 3.6 170 +/- 5.9 |
12.4 mg/m^3 124 +/- 2.6 138 +/- 4.5 |
P < 0.001 P < 0.001 |
Respiratory rate (per minute) Month 2 |
Control 170.0 +/- 5.9 |
1.4 mg/m^3 146.0 +/- 3.3 |
P > 0.002 |
Olfactory Acuity |
Control |
1.4 mg/m^3 Decreased |
|
Disruptions of Cardiovascular, Nervous and Endocrine Systems |
Control |
12.4 mg/m^3 1.4 mg/m^3 Present |
|
Decreased Nervous Excitability Measured in units Month 3 |
Control 3.8 +/- 0.13 |
1.4 mg/m^3 5.1 +/- 0.2 |
P < 0.001 |
Endocrine Effects: 131I absorption by thyroid: Month 2 Month 4 |
Control 14.5 +/- 1.3% 24.3 +/- 2.9% |
1.4 mg/m^3 38.4 +/- 5.3% 9.1 +/- 0.74% |
P < 0.001 P < 0.001 |
Effect on organ weight coefficients: Thyroid: Month 2 Adrenal: Month 3 |
Control 5.7 +/- 0.21 17 +/- 0.79 |
1.4 mg/m^3 6.8 +/- 0.31 21 +/- 1.19 |
P = 0.01 P = 0.02 |
Histopathology of nose mucous membranes Histopathology of liver, kidneys |
12.4 mg/m^3 1.4 mg/m^3 Effects seen 12.4 mg/m^3 |
Increased thickness of mucous membrane and submucosal layer, edema, increased epithelial goblet cells, desquamation of epithelial cells, increased mucous in open passages moderate protein dystrophy in kidneys, liver |
|
No adverse effects seen |
Control |
0.16 mg/m^3 |
Applicant's summary and conclusion
- Conclusions:
- A 4 month bromine inhalation exposure study in rats produced a No adverse effects concentration of 0.16 mg/m^3 (0.02 ppm). The lowest concentration producing effects was 1.4 mg/m^3 (0.2 ppm) for a 4 month exposure. Effects were seen in the respiratory, olfactory and endocrine systems, although these effects were less pronounced than those seen with exposure to 12.4 mg/m^3 (1.9 ppm), and the effects were reversible as demonstrated in a 1 month recovery group. The LIMir concentration (12.4 mg/m^3) produced signs of pronounced toxicity. A parallel study in rabbits showed similar effects - with the respiratory system as the main target organ.
- Executive summary:
A 4 month bromine inhalation exposure study in rats produced a no adverse effects concentration of 0.16 mg/m^3 (0.02 ppm). The lowest concentration producing effects was 1.4 mg/m^3 (0.2 ppm) for a 4 month exposure. Effects were seen in the respiratory, olfactory and endocrine systems, although these effects were less pronounced than those seen with exposure to 12.4 mg/m^3 (1.9 ppm), and the effects were reversible as demonstrated in a 1 month recovery group. The LIMir concentration (12.4 mg/m^3) produced signs of pronounced toxicity. A parallel study in rabbits showed similar effects - with the respiratory system as the main target organ.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.